View Older Stories View More Recent Stories

Oct 7, 2021 04:05PM BeiGene Announces First Regulatory Approval in Australia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Waldenström’s Macroglobulinemia
Sep 20, 2021 07:00AM BeiGene Announces Inclusion in FTSE Russell Indices
Sep 17, 2021 08:01AM BeiGene (BGNE) Announces Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of Adults with Waldenström’s Macroglobulinemia
Sep 17, 2021 08:00AM BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of Adults with Waldenström’s Macroglobulinemia
Sep 15, 2021 07:03AM BeiGene (BGNE) BRUKINSA® Granted Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma
Sep 15, 2021 07:00AM U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma
Sep 13, 2021 06:18AM BeiGene (BGNE) Announces U.S. FDA Acceptance of BLA for Tislelizumab in Esophageal Squamous Cell Carcinoma
Sep 13, 2021 12:00AM BeiGene Announces U.S. FDA Acceptance of Biologics License Application for Tislelizumab in Esophageal Squamous Cell Carcinoma
Sep 12, 2021 06:05PM BeiGene to Present Latest Findings in Robust Lung Cancer Portfolio at ESMO Congress 2021
Sep 1, 2021 05:39PM BeiGene (BGNE) Granted FDA Approval for BRUKINSA to Treat WM
Sep 1, 2021 05:33PM U.S. FDA Grants BRUKINSA® (Zanubrutinib) Approval in Waldenström’s Macroglobulinemia
Aug 23, 2021 05:31AM BeiGene (BGNE) Announces Acceptance of Chinese Supplemental Biologics License Application for Tislelizumab
Aug 22, 2021 07:00PM BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Nasopharyngeal Cancer
Aug 18, 2021 01:00AM BeiGene Announces Acceptance by Swissmedic of Marketing Authorization Application for BRUKINSA® (Zanubrutinib) in Waldenström’s Macroglobulinaemia
Aug 17, 2021 09:23AM BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA® (Dinutuximab Beta) for Patients With High-Risk Neuroblastoma
Aug 17, 2021 07:10AM BeiGene (BGNE) and EUSA Pharma Announce China NMPA Approval of QARZIBA® (Dinutuximab Beta) for Patients with High-Risk Neuroblastoma
Aug 17, 2021 07:00AM BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA® (Dinutuximab Beta) for Patients with High-Risk Neuroblastoma
Aug 16, 2021 07:00AM BeiGene to Host Investor Conference Call and Webcast to Discuss the Company’s Early Development Pipeline and Research on August 25, 2021
Aug 5, 2021 04:05PM BeiGene Reports Second Quarter 2021 Financial Results
Aug 3, 2021 07:00AM BeiGene Announces Plans to Build New Manufacturing and Clinical R&D Center at Princeton West Innovation Park in Hopewell, New Jersey
Jul 30, 2021 05:21AM BeiGene (BGNE) Announces Positive opline Results from Phase 3 SEQUOIA Trial of BRUKINSA® (Zanubrutinib)
Jul 29, 2021 08:00PM BeiGene Announces Positive Topline Results from Phase 3 SEQUOIA Trial Comparing BRUKINSA® (Zanubrutinib) to Bendamustine Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
Jul 26, 2021 07:05AM BeiGene (BGNE) Announces Approval in Canada of BRUKINSA for the Treatment of Patients with Mantle Cell Lymphoma BGNE:
Jul 26, 2021 07:00AM BeiGene Announces Approval in Canada of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Mantle Cell Lymphoma
Jul 9, 2021 06:20AM BeiGene (BGNE) Announces the Approval in China of KYPROLIS for Injection for Adult Patients with R/R Multiple Myeloma
Jul 9, 2021 12:00AM BeiGene Announces the Approval in China of KYPROLIS® (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple Myeloma
Jul 7, 2021 08:00PM BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC)
Jul 7, 2021 07:07AM PureTech (PRTC) Announces Clinical Trial and Supply Agreement with BeiGene (BGNE) to Evaluate LYT-200 and Tislelizumab in Patients with Difficult-to-Treat Solid Tumors
Jul 7, 2021 07:00AM PureTech Announces Clinical Trial and Supply Agreement with BeiGene to Evaluate LYT-200 and Tislelizumab in Patients with Difficult-to-Treat Solid Tumors
Jun 23, 2021 06:18AM BeiGene (BGNE) Announces China NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and Hepatocellular Carcinoma
Jun 23, 2021 12:00AM China NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and Hepatocellular Carcinoma
Jun 18, 2021 04:30PM BeiGene (BGNE) Announces China NMPA Approval of BRUKINSA for Treatment of Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia
Jun 18, 2021 04:30PM BeiGene Announces China NMPA Approval of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Waldenström’s Macroglobulinemia
Jun 17, 2021 07:00AM BeiGene Announces First Patient Dosed in Global Phase 3 Trial of Anti-TIGIT Antibody Ociperlimab in Non-Small Cell Lung Cancer
Jun 11, 2021 03:00AM BeiGene Presents Long-Term Efficacy and Safety Results from Three Pivotal Trials of BRUKINSA® (Zanubrutinib) and Tislelizumab at EHA2021
Jun 11, 2021 03:00AM BeiGene Presents ALPINE Results at EHA2021 Demonstrating Both Efficacy and Safety Advantages of BRUKINSA® (Zanubrutinib) in Head-to-Head Comparison to Ibrutinib in Chronic Lymphocytic Leukemia
Jun 9, 2021 07:00AM Shoreline Biosciences and BeiGene Announce Strategic Worldwide Collaboration to Develop and Commercialize Genetically Modified Natural Killer (NK) Cell Therapies
Jun 7, 2021 05:01PM BeiGene (BGNE) Announces Acceptance of sBLA in China for Tislelizumab in Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors
Jun 7, 2021 05:00PM BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) Solid Tumors
Jun 4, 2021 09:00AM BeiGene Presents Clinical Data from Two Pivotal Trials of Tislelizumab at the 2021 ASCO Annual Meeting
Jun 4, 2021 09:00AM BeiGene Presents Clinical Data from Two Phase 2 Trials of Pamiparib at the 2021 ASCO Annual Meeting
Jun 1, 2021 10:02AM BeiGene (BGNE) Announces First Presentation of Phase 3 ALPINE Trial Comparing BRUKINSA to Ibrutinib in Chronic Lymphocytic Leukemia to Be Featured in Presidential Symposium at EHA2021
Jun 1, 2021 10:00AM BeiGene Announces First Presentation of the Phase 3 ALPINE Trial Comparing BRUKINSA® (Zanubrutinib) to Ibrutinib in Chronic Lymphocytic Leukemia to Be Featured in Presidential Symposium at EHA2021
May 21, 2021 07:02AM BeiGene (BGNE) Reports Positive Topline Results from Phase 3 Trial of Tislelizumab
May 21, 2021 07:00AM BeiGene Announces Positive Topline Results from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
May 19, 2021 05:00PM BeiGene to Showcase Broad Clinical Portfolio at 2021 ASCO Annual Meeting
May 19, 2021 07:01AM BeiGene (BGNE) Announces U.S. FDA Acceptance and Priority Review of sNDA for BRUKINSA in Marginal Zone Lymphoma
May 19, 2021 07:00AM BeiGene Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for BRUKINSA® (Zanubrutinib) in Marginal Zone Lymphoma
May 12, 2021 10:05AM BeiGene (BGNE) Highlights Progress in Hematology at EHA2021 Virtual Congress
May 12, 2021 10:00AM BeiGene Highlights Progress in Hematology at EHA2021 Virtual Congress
View More Recent Stories View Older Stories